# Contents


**1. Key Definitions in Pharmacovigilance** **1**
Renu Agarwal, SK Gupta
- Sources 7

**2. Pharmacovigilance: Historical Perspective** **9**
Renu Agarwal, SK Gupta
- Pharmacovigilance before 18th Century 9
- Pharmacovigilance in 18th Century 9
- Pharmacovigilance in 19th Century 11
- Pharmacovigilance in 20th Century: Prethalidomide Era 11
- Pharmacovigilance in 20th Century: Thalidomide Disaster and Post-thalidomide Era 13
- McBride's Famous Letter to the Lancet Thalidomide Infant 13
- Pharmacovigilance: The Current Status 14
- Pharmacovigilance: The Current System in India 14

**3. Pharmacovigilance: Need and Objectives** **17**
Renu Agarwal
- Need for Pharmacovigilance and Widening Horizons 17
- Purpose of Pharmacovigilance 19
- Specific Aims of Pharmacovigilance in View of Widening Horizons 19
- Priority Areas of Pharmacovigilance 19
- Outcome and Impact of Current System 21

**4. Current Methods of Pharmacovigilance** **25**
Arani Chatterjee, Manoj Sharma, SK Gupta
- Methods for Vaccine Safety 33

**5. Adverse Drug Reactions: Classification, Mechanism and Interaction** **40**
SK Gupta, Manoj Sharma, Arani Chatterjee
- Adverse Event (or Adverse Experience) 40
- Adverse Drug Reaction (ADR) 40
- Adverse Drug Reactions: Importance 41
- Risk Factors for Adverse Drug Reactions 42
- Pharmacological Classification 44
- Causality Classification (WHO-UMC Classification) 45
- Severity Classification 47
- Seriousness Classification 47
- Frequency Classification 48
- Mechanism Classification 48
- Statistical Classification 49

- Mechanism of Adverse Drug Reactions 49
- Adverse Drug Interactions 56

**6. Signal Detection in Pharmacovigilance** **63**
Renu Agarwal, Puneet Agarwal

- Sources and Methods of Signal Detection 65
- Automated Quantitative Signal Detection 69
- Application of Quantitative Methods for Signal Detection 71
- Vigi Methods and Tools 72
- The UMC Signaling Process 73
- WHO and UMC Leadership in Signal Detection 74

**7. Postmarketing Surveillance** **77**
Manoj Sharma, SK Gupta

- Need of Postmarketing Surveillance: Why 78
- Postmarketing Surveillance Methodologies 80

**8. Setting up of a Pharmacovigilance Centre** **100**
Sushma Srivastava

- Initiation of Drug Monitoring Centres 101
- Practicalities in the Organization of a Pharmacovigilance Centre 102
- Pharmacovigilance Centres in India 108
- Pharmacovigilance Programme of India (PvPI) 109

**9. Benefit-Risk Assessment in Pharmacovigilance** **111**
Renu Agarwal, SK Gupta

- Adverse Health Effect 111
- Actual Versus Perceived Benefits and Risks 112
- Benefit-Risk Assessment: A Dynamic Process 112
- Factors Affecting Benefit-Risk Balance 114
- Stepwise Approach to Benefit-Risk Assessment 115
- Benefit-Risk Assessment 116
- Semi-Quantitative and Quantitative Approach to Benefit-Risk Assessment 117
- Option Analysis 122
- Decision-Making 123

**10. Crisis Management in Pharmacovigilance** **127**
Renu Agarwal, Puneet Agarwal

- "Crisis": Definition 127
- The Key Characteristics of a Crisis 127
- "Crisis" in Pharmacovigilance 128
- Stakeholders 128
- The Threat Sources for Crisis in Pharmacovigilance 129
- Crisis Management 129
- Crisis Management Cycle 130
- Crisis Management Model 131
- Planning for Crisis Management 133

- Additional Activities that Favor "Crisis Prepared" Organizational Structures 138
- Crisis Prevention Principles 139

**11. WHO Pharmacovigilance: Programme for Global Drug Monitoring 141**
Sushma Srivastava, SK Gupta

- Role of WHO Programme for International Drug Monitoring 143
- Global Pharmacovigilance 147
- Joining the WHO Programme for International Drug Monitoring 148

**12. Pharmacovigilance of Herbal Drugs 150**
Rajani Mathur, SK Gupta

- Introduction: What are Herbal Medicines? 150
- Herbal Medicines: Are they Really Safe? 152
- Challenges Relating to the Safety Monitoring of Herbal Drugs 153
- Mechanisms Underlying ADR due to Herbal Drugs 155
- Pharmacovigilance of Herbal Medicines: Definitions, Goals and Need 157
- Adverse Event Reporting 158
- Adverse Event Reporting: The UK Lead 160
- Traditional Chinese Medicines: Boon or Bane? 161
- Measures to Improve the Pharmacovigilance of Herbal Medicines 161

**13. Medical Dictionary for Regulatory Activities: An Overview 165**
Sanjeev Miglani, Arun Gupta, Mugdha Chopra

- Objectives of MedDRA 165
- Applications of MedDRA 165
- Regulatory Status/Historical Overview 166
- MedDRA Structure 166
- MedDRA Rules 168
- Criteria for Term Selection 168
- MedDRA Versioning 172
- Standardized MedDRA Queries (SMQs) 172
- MedDRA and SMQ in Signal Detection 172

**14. Pharmacogenetics and Pharmacovigilance 174**
Rajani Mathur

- Adverse Drug Reactions: A Clinical Problem 174
- Why ADRs do not Affect Everybody Equally? 174
- Polymorphism in Genes Encoding Pharmacokinetic Parameters and ADRs 175
- Polymorphism in Genes 176
- Encoding Pharmacodynamic Parameters and ADRs 176
- Practical Challenges of Pharmacogenomics 177
- The Way Forward 177

**15. Pharmacovigilance Regulations in Various Countries 180**
Sushma Srivastava, SK Gupta, Mohit Hans

- Pharmacovigilance in Europe 180
- Process of Regulatory Pharmacovigilance 182

- United Kingdom 184
- France 188
- Brazil 190
- India 190
- China 193
- Japan 195
- Australia 196
- Canada 197
- United States of America 198

**16. Pharmacoepidemiology and Pharmacovigilance 209**
SK Gupta, Mohit Hans, Sushma Srivastava

- Methodologies in Pharmacoepidemiologic Studies 211
- Pharmacoepidemiology in Drug Development 214

**17. Hospitalization due to Adverse Drug Reactions and its Economic Burden 216**
SK Gupta, Mohit Hans, Sushma Srivastava

- Economic Burden of ADRs 219
- Types of Cost 221
- Cost of ADRs 222

**18. Vigilance Systems for Medical Devices 225**
SK Gupta, Sushma Srivastava, Mohit Hans

- Medical Device Regulations and Need for Harmonization 240
- Medical Device Regulations 243
- Medical Device Market: Focusing BRICS 247

**19. Data Mangement in Pharmacovigilance 251**
Kamal Akhtar, Manoj Sharma

- Role of Software/Computer-based Systems 251
- Methods of Safety Data Analysis 254
- Informatics in Pharmacovigilance—A New Paradigm 255
- Emerging Technologies/Computer-based Tools for Pharmacovigilance 259
- WebSDM™ for Analysis of Premarketing Safety Data 260
- MGPS and HBLR for Analysis of Postmarketing Data 260
- Drug Safety Technology Vendors 261
- Vendor Profile—ARIS GLOBAL 261
- ARIS GLOBAL Total Safety Suite 261
- Vendor Profile – Galt Associates Inc 263
- Vendor Profile – Insightful 263
- Vendor Profile – Oracle Corp 264
- Vendor Profile – Phase Forward 264
- Vendor Profile – Relsys Inc. 265
- Vendor Profile – eResearch Technologies (eRT) 265
- Vendor Profile – SAIC 266

- Vendor Profile - SAS 266
- Case Studies 267
- Data Mining and Signal Detection 268
- Uppsala Monitoring Center 269


**Annexures**


- **Annexure 1A and B:** ADR Forms: India 271
- **Annexure 2A and B:** Yellow Card: MHRA 275
- **Annexure 3A to C:** MedWatch Forms (US-FDA 3500, 3500A & 3500B) 279
- **Annexure 4:** First Information Report (FIR) 299
- **Annexure 5:** Preliminary Investigation Report (PIR) 302
- **Annexure 6:** Detailed Investigation Report (DIR) 309
- **Annexure 7:** AEFI- Laboratory Requisition Form (LRF) 314
- **Annexure 8:** Good Vigilance Practices Guidelines 316
- **Annexure 9:** ADR Report Form in English: China 596
- **Annexure 10:** Blue Card: Australia 598
- **Annexure 11A to C:** ADR Forms: Canada 600

*Index* *611*